Holen Sie sich die Stockscreener-App
1.58
0.04%
0.01
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt FBIO?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$1.57
Offen:
$1.63
24-Stunden-Volumen:
208.07K
Relative Volume:
0.36
Marktkapitalisierung:
$43.20M
Einnahmen:
$80.97M
Nettoeinkommen (Verlust:
$-78.31M
KGV:
-0.1064
EPS:
-14.85
Netto-Cashflow:
$-129.56M
1W Leistung:
+0.04%
1M Leistung:
-11.76%
6M Leistung:
-20.68%
1J Leistung:
-28.61%
1-Tages-Spanne:
$1.55
$1.6399
1-Wochen-Bereich:
$1.41
$1.6399
52-Wochen-Spanne:
$1.355
$4.43
Fortress Biotech Inc Stock (FBIO) Company Profile
Firmenname
Fortress Biotech Inc
Sektor
Branche
Telefon
781-652-4500
Adresse
1111 KANE CONCOURSE, BAY HARBOR ISLANDS, NY
Vergleichen Sie FBIO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| FBIO | 1.58 | 43.20M | 80.97M | -78.31M | -129.56M | -14.85 |
| VRTX | 449.81 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 748.65 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 590.61 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 247.57 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 107.19 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Fortress Biotech Inc Stock (FBIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-03-15 | Fortgesetzt | ROTH MKM | Buy |
| 2022-08-04 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2020-10-02 | Eingeleitet | The Benchmark Company | Buy |
| 2019-12-18 | Eingeleitet | B. Riley FBR | Buy |
| 2018-02-28 | Eingeleitet | B. Riley FBR, Inc. | Buy |
| 2017-07-11 | Eingeleitet | Rodman & Renshaw | Buy |
| 2017-03-22 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2016-10-03 | Eingeleitet | ROTH Capital | Buy |
Alle ansehen
Fortress Biotech Inc Aktie (FBIO) Neueste Nachrichten
Fortress Biotech price target raised to $15 from $13 at Roth MKM - TipRanks
Fortress Biotech price target lowered to $4 from $5 at Alliance Global Partners - TipRanks
Fortress Biotech price target raised to $26 from $24 at H.C. Wainwright - TipRanks
Fortress Biotech (FRA:CNB1) Total Inventories : €9.00 Mil (As of Jun. 2024) - GuruFocus.com
Fortress Biotech Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance
Fortress Biotech: Q3 Earnings Snapshot - mySA
Fortress Biotech Inc. (FBIOP) Quarterly 10-Q Report - Quartz
Fortress Biotech’s Q3 2024 Earnings and FDA Milestone - TipRanks
Fortress Biotech Q3 2024 Earnings: EPS Loss of $0.76 Beats Estimate, Revenue of $14.63M Misses Expectations - GuruFocus.com
Fortress Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights - GlobeNewswire
Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights - GlobeNewswire
Avenue Therapeutics Reports $3.1M Q3 Loss, Advances Key Clinical Trials Pipeline | ATXI Stock News - StockTitan
Mustang Bio gets extension for Nasdaq compliance By Investing.com - Investing.com South Africa
Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates - GlobeNewswire
Checkpoint Therapeutics Sets FDA Review Date, Secures $9.2M Funding Boost Amid Q3 Loss | FBIO Stock News - StockTitan
Journey Medical's Mixed Q3: FDA Win for Rosacea Drug Despite Revenue Dip | FBIO Stock News - StockTitan
Mustang Bio gets extension for Nasdaq compliance - Investing.com
Mustang Bio Receives Positive Listing Determination from Nasdaq - The Manila Times
Mustang Bio Secures Critical Nasdaq Extension, Faces January 2025 Deadline for $1 Compliance | MBIO Stock News - StockTitan
Where are the Opportunities in (FBIOP) - Stock Traders Daily
Mustang Bio gains FDA Orphan Drug Status for glioma treatment - Investing.com India
Mustang Bio Granted Orphan Drug Designation by U.S. FDA for - GlobeNewswire
Mustang Bio gains FDA Orphan Drug Status for glioma treatment By Investing.com - Investing.com UK
How To Trade (FBIOP) - Stock Traders Daily
Fortress Biotech Insiders Placed Bullish Bets Worth US$4.49m - Yahoo Finance
Biotech Stocks Facing FDA Decision In November 2024 - RTTNews
Fortress Biotech, Inc.'s (NASDAQ:FBIO) Shares Bounce 36% But Its Business Still Trails The Industry - Simply Wall St
Mustang Bio, Inc. Appoints David Jin as A Member of the Board - Marketscreener.com
Highbridge Capital Management's Strategic Acquisition of Fortress Biotech Shares - Yahoo Finance
Highbridge Capital Management's Strategic Acquisition of Fortres - GuruFocus.com
Journey Medical Corporation Announces DFD-29 Data Presented at 44th Fall Clinical Dermatology Conference - GlobeNewswire
Mustang Bio secures $4 million from warrant exercises - Investing.com India
Mustang Bio secures $4 million from warrant exercises By Investing.com - Investing.com South Africa
Mustang Bio Announces Exercise of Warrants for $4 Million Gross Proceeds - The Manila Times
Avenue Therapeutics to Participate in Maxim Group's 2024 Healthcare Virtual Summit - The Manila Times
Avenue Therapeutics to Participate in Maxim Group’s 2024 Healthcare Virtual Summit - GlobeNewswire
Analysts review Fortress Biotech Inc’s rating - Knox Daily
Was there any good news for Fortress Biotech Inc (FBIO) stock in the last session? - US Post News
PRESIDENT, CEO & CHAIRMAN ROSENWALD LINDSAY A MD acquire 763,359 shares of Fortress Biotech Inc [FBIO] - Knox Daily
Journey Medical Corporation to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference - GlobeNewswire
Finanzdaten der Fortress Biotech Inc-Aktie (FBIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Fortress Biotech Inc-Aktie (FBIO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| ROSENWALD LINDSAY A MD | President, CEO & Chairman |
Jul 11 '24 |
Buy |
7.48 |
5,000 |
37,418 |
127,500 |
| Jin David | Chief Financial Officer |
Jul 10 '24 |
Buy |
7.50 |
500 |
3,750 |
500 |
| ROSENWALD LINDSAY A MD | President, CEO & Chairman |
Jul 09 '24 |
Buy |
7.39 |
5,000 |
36,971 |
122,500 |
| ROSENWALD LINDSAY A MD | President, CEO & Chairman |
Jul 08 '24 |
Buy |
7.35 |
5,000 |
36,764 |
117,500 |
| ROSENWALD LINDSAY A MD | President, CEO & Chairman |
Jun 28 '24 |
Buy |
1.64 |
20,000 |
32,724 |
2,893,905 |
| ROSENWALD LINDSAY A MD | President, CEO & Chairman |
May 16 '24 |
Buy |
1.76 |
10,000 |
17,589 |
2,873,905 |
| Klein Dov | Director |
May 20 '24 |
Sale |
1.89 |
10,000 |
18,900 |
53,400 |
| ROSENWALD LINDSAY A MD | President, CEO & Chairman |
Jan 05 '24 |
Buy |
2.38 |
50,000 |
118,770 |
2,863,905 |
1.80%
0.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):